About Us

The Company operates Polomar Specialty Pharmacy, LLC, a Florida-licensed compounding pharmacy that provides both sterile and non-sterile compounded prescription medications and is currently authorized to serve patients in 22 states. Management’s strategic focus is to expand the pharmacy’s geographic reach and capitalize on growing demand for compounded GLP-1 weight-loss therapies and other specialized medications. The Company expects Polomar Pharmacy to become an NABP certified compounding pharmacy in December of this year which will provide increased access to additional U.S. states.

Since acquiring Polomar Pharmacy in September 2024, the Company has transitioned from a predominantly local dermatology-focused pharmacy to a national prescription fulfillment platform. This transformation has included obtaining sterile compounding capabilities, building relationships with telehealth providers, and expanding prescription fulfillment services for compounded GLP-1 medications. A key milestone was the execution of a pharmacy services agreement with CareValidate in 2025, which began generating revenue through prescription fulfillment for telehealth patients.

The Company also plans to launch SlimRx™, a telehealth platform focused on weight-loss treatment during the fourth quarter of 2026. SlimRx is expected to connect patients with licensed healthcare providers and generate prescription volume that will be fulfilled by Polomar Pharmacy, creating an integrated patient acquisition and fulfillment model. Additionally, the Company is preparing to introduce PoloMedsTM a concierge health, wellness and longevity platform that will assist members with access to additional healthcare support including lab testing, personalized plans incorporating prescription medications, supplements and data driven analytics.